University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Location status: Recruiting
Location contact
Amy Bodde, PhD
CONTACT
Amy Bodde, PhD
PRINCIPAL_INVESTIGATOR
Joseph Sherman
CONTACT
NCT Number: NCT07425769
The goal of this clinical trial is to observe feasibility and initial efficacy of a remotely delivered exercise and dementia caregiving intervention in older adults with Down syndrome and their caregivers.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Kansas City, Kansas, 66160, United States
Location status: Recruiting
Amy Bodde, PhD
CONTACT
Amy Bodde, PhD
PRINCIPAL_INVESTIGATOR
Joseph Sherman
CONTACT
In Adapting RDAD for DS Phase 3 (CareFit-DS/AD), we will conduct a 12-week, single arm pilot trial intervention in 20 adults with DS/caregiver dyads. This intervention includes remote-delivered functional exercise classes for adults with DS and their caregivers, and remote delivered dementia caregiving training sessions for the caregivers. Participants with DS will complete 12 weeks of group exercise sessions (three ~30-minute sessions per week, caregiver optional) over video call, and caregivers will also receive a weekly ~40-minute group video call session of a dementia caregiver training/support group.
Staff will travel to participant homes at baseline and following 12 weeks to perform assessments of physical function and to set up the Actigraph accelerometers. Saliva collection kits for caregivers will be mailed ahead of time and picked up at the home visit. Additionally, at baseline staff will deliver equipment for intervention delivery
Twelve unique pre-recorded exercise class sessions (endurance, strength, balance, and flexibility) will be performed 3 times each throughout the study (36 sessions total). The exercise session content and frequency are designed to improve functional fitness for daily activities and will challenge participants at a light and/or moderate intensity level. During the sessions, all participants will join a video call and follow along with a pre-recorded exercise video in a group format. A staff member trained in working with the population will be on the call to provide encouragement and feedback, while monitoring for participant safety. Caregivers may attend and participate in the exercise sessions, but will neither be encouraged or discouraged from doing so.
Caregivers will be asked to attend weekly group behavioral management training sessions via video call immediately following one of the 3 exercise sessions. These meetings will consist of information and resources for caregiving for a person with DS who has been diagnosed with dementia. The group will be moderated by a staff member trained in working with the population and will include presented information as well as group discussion time. Topics include the Overview of Alzheimer's Disease in Down Syndrome; Behavior Management Strategies, Changing Expectations, etc.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adults with Down syndrome:
Exclusion criteria
- Adults with Down syndrome:
Inclusion criteria
- Caregivers
Exclusion criteria
- Caregivers
Participants will take part in thrice weekly exercise sessions using pre-recorded videos designed for older adults with Down syndrome. Participants will join video call and follow along with the video. A staff member familiar with the population will be on the call to provide modifications, encouragement and ensure participant safety.
Caregivers will join a once-weekly education session held via video call and led by a trained staff member. Education content will include how to support and manage challenging behaviors of older adults with Down syndrome who may be experiencing Alzheimer's disease-related symptoms.
Time frame: Baseline
Number of participants enrolled divided by number eligible on questionnaire
Time frame: Baseline
Number of participants enrolled per month of active recruitment
Time frame: Baseline to Week 12
Calculated as number of participants completing the intervention divided by the number who initiate the intervention multiplied by 100
Time frame: Across 12 week intervention
Calculated as the percentage of sessions attended across 12 weeks.
Time frame: Across 12 week intervention
Will be expressed as the total number of self-reported adverse events.
Time frame: Baseline and Week 12
Assessed using an ActiGraph wGT3x-BT accelerometer (ActiGraph LLC, Pensacola, FL) worn on the non-dominant wrist over 7 consecutive days.
Time frame: Baseline and Week 12
Light, moderate and vigorous physical activity will be assessed using an ActiGraph wGT3x-BT accelerometer (ActiGraph LLC, Pensacola, FL) worn on the non-dominant wrist over 7 consecutive days.
Time frame: Baseline and Week 12
Time required to stand up and return to seated position 5 times. Lower time indicates increased physical function.
Time frame: Baseline and Week 12
Time required to stand from a chair, walk 3 meters, pivot around a cone and return to a seated position. Lower times indicate increased physical function.
Time frame: Baseline and Week 12
Number of steps with knees reaching a height of the midpoint of the femur participants are able to complete in 2 minutes. Higher scores indicate increased physical function.
Time frame: Baseline and Week 12
The FICSIT-4 assesses static balance by positioning participants in 4 different stances: feet side-by-side; feet semi-tandem; feet tandem; and one foot. Each stance is attempted to be held for 10 seconds. Higher scores indicate improved physical function.
Time frame: Baseline and Week 12
Grip strength for both the dominant and non-dominant hands will be assessed in triplicate and then scores averaged. Higher number indicate increased physical function.
Time frame: Baseline and Week 12
Will be assessed by proxy (caregiver report) using the 17-item Waisman Activities of Daily Living survey. Higher scores indicate increased independence with ADLs.
Time frame: Baseline and Week 12
Will be assessed by proxy report with the Neuropsychiatric Inventory Questionnaire (NPI-Q). Higher scores indicate increased frequency and severity of behavioral symptoms.
Time frame: Baseline and Week 12
Assessed using an ActiGraph wGT3x-BT accelerometer (ActiGraph LLC, Pensacola, FL) worn on the non-dominant wrist over 7 consecutive days.
Time frame: Baseline and Week 12
Light, moderate and vigorous physical activity will be assessed using an ActiGraph wGT3x-BT accelerometer (ActiGraph LLC, Pensacola, FL) worn on the non-dominant wrist over 7 consecutive days.
Time frame: Baseline and Week 12
Time required to stand up and return to seated position 5 times. Lower time indicates increased physical function.
Time frame: Baseline and Week 12
Time required to stand from a chair, walk 3 meters, pivot around a cone and return to a seated position. Lower times indicate increased physical function.
Time frame: Baseline and Week 12
Number of steps with knees reaching a height of the midpoint of the femur participants are able to complete in 2 minutes. Higher scores indicate increased physical function.
Time frame: Baseline and Week 12
The FICSIT-4 assesses static balance by positioning participants in 4 different stances: feet side-by-side; feet semi-tandem; feet tandem; and one foot. Each stance is attempted to be held for 10 seconds. Higher scores indicate improved physical function.
Time frame: Baseline and Week 12
Grip strength for both the dominant and non-dominant hands will be assessed in triplicate and then scores averaged. Higher number indicate increased physical function.
Time frame: Baseline and Week 12
Will be assessed using the Modified Caregiver Strain Index which captures multiple domains of caregiver strain (physical, emotional, financial). Higher scores indicate greater burden and need for support or intervention.
Time frame: Baseline and Week 12
Will be assessed by the Measure of Unmet Needs survey. Higher scores indicate larger amounts of unmet caregiver needs.
Time frame: Baseline and Week 12
Will be measured using a 9-item dementia caregiver self-efficacy measure. Caregivers will rate their certainty of handling challenging behaviors and access to community services. Higher scores indicate higher self-efficacy.
Time frame: Baseline and Week 12
Will be assessed with the Multidimensional Scale of Perceived Social Support (MSPSS). The MSPSS is a 12-item measure of perceived social support measured on a total sum scale and on 3 domains: family, friends, and significant others. Higher scores indicate increased perception of social support.
Time frame: Baseline and Week 12
Will be measured with the Center for Epidemiologic Studies Depression Scale. Higher scores indicate increased caregiver depression risk.
Time frame: Baseline and Week 12
Will be measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Higher scores indicate increased anxiety symptoms.
Time frame: Baseline and Week 12
Will be assessed by a subscale of NPI-Q. higher scores indicate increase symptom-related caregiver distress.
Time frame: Baseline and Week 12
Will be measured by collection and analysis of salivary cortisol. Higher levels of salivary cortisol are correlated with increased stress.
Time frame: Week 12
Will be assessed from audio recorded semi-structured interviews conducted with adult with DS/caregiver dyads within 2 weeks following completion of the 12 week intervention
Contact information is provided by the study sponsor or research team.
University of Kansas Medical Center
Other
Adapting the RDAD Intervention for Individuals With Down Syndrome Phase 3- Pilot Test
Acronym: CareFit DS/AD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07234695
Abnormalities, Multiple, Alzheimer Blood Biomarkers
Granada, Andalusia, Spain
View Trial DetailsNCT06911944
Abnormalities, Multiple, Alzheimer Disease
View Trial DetailsNCT01699711
Abnormalities, Multiple, Alzheimer Disease
Barcelona, Spain
View Trial DetailsNCT07135167
Abnormalities, Multiple, Chromosome Disorders
Atlanta, Georgia, United States
View Trial Details